The CUP-DIU study explored the relationship between IUD displacement and the use of a menstrual cup in 747 women who consulted for follow-up of their IUD at 2 primary care facilities in Paris.

Participants received 480 mg of nivolumab and 160 mg of relatlimab intravenously once every 4 weeks for two cycles before ...

Penpulimab-kcqx, a humanized immunoglobulin G1 monoclonal antibody, blocks the interaction between the programmed death 1 receptor on T-cells and programmed death ligand 1 and 2 on tumor cells.

The FDA has granted accelerated approval to Datroway for adults with previously-treated, locally advanced or metastatic EGFR-mutated NSCLC.

The FDA has approved Gamifant for the treatment of adult and pediatric patients with HLH/MAS in known or suspected Still disease.

The Food and Drug Administration (FDA) has granted accelerated approval to Lynozyfic™ (linvoseltamab-gcpt) for the treatment of adult patients with ...

The Food and Drug Administration has approved Harliku (nitisinone) for the reduction of urine homogentisic acid in adult patients with alkaptonuria.

MPR set a new goal of $1 million for its upcoming membership drive, while TPT has made cuts.

In an email to members, MPR said they are going to work to raise at least $1 million during the MPR Spring Member Drive that begins next week.

Cancer patients may have an increased risk of developing second primary malignancies after immune checkpoint inhibitor therapy.

Embattled TikTok has been key to online growth, but MPR News says its vertical content is built to reach younger audience on any platform.